ClinicalTrials.gov
public full text
Public Domain
Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)
SC291-102 is a Phase 1 study to evaluate SC291 safety and tolerability, preliminary clinical response, cellular kinetics and exploratory assessments for subjects with severe autoimmune diseases.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- The Safety and Efficacy of Telitacicept in the Treatment of Systemic Sclerosis#883509
- Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases#1164029
- Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)#804904
- Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy#891131
- A Pan-TB Regimen Targeting Host and Microbe#888951
Record · ID 830801
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive